Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardio Diagnostics HoldingsCDIO -6.94%53 Days Sales Outstanding is 73.00 as of Jun. 2026, which is 78% below its 10-year median of 328.50. GuruFocus rates CDIO with a GF Scoreâ„¢ of 53/100 and a GF Valueâ„¢ of $1.80 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 838 Biotechnology companies, Cardio Diagnostics Holdings ranks worse than 86.28% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardio Diagnostics Holdings Days Sales Outstanding Chart
CDIO vs ERNA, LABT, JAGX: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Cardio Diagnostics Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardio Diagnostics Holdings Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Cardio Diagnostics Holdings's Days Sales Outstanding falls into.
Cardio Diagnostics Holdings Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardio Diagnostics Holdings (CDIO) has a Days Sales Outstanding of 73.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cardio Diagnostics Holdings and its competitors. This is 78% below median its historical median of 328.50. Over the past decade, Cardio Diagnostics Holdings' Days Sales Outstanding has ranged from 107.35 to 365.00. According to the industry distribution chart, Cardio Diagnostics Holdings ranks #723 out of 838 companies in the Biotechnology industry, placing it in the top 86.3%.
Is Cardio Diagnostics Holdings' Days Sales Outstanding too high?
Cardio Diagnostics Holdings' current Days Sales Outstanding of 73.00 is 78% below median its 10-year median of 328.50. Over the past 10 years, this metric has ranged from a low of 107.35 to a high of 365.00. The Biotechnology industry median Days Sales Outstanding is 69.00. Cardio Diagnostics Holdings' value of 73.00 is 5.8% above this industry median. Based on the distribution chart, Cardio Diagnostics Holdings ranks #723 out of 838 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cardio Diagnostics Holdings has a GF Scoreâ„¢ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cardio Diagnostics Holdings' Days Sales Outstanding compare to ERNA and LABT?
According to the Biotechnology industry distribution chart, Cardio Diagnostics Holdings ranks #723 out of 838 companies for Days Sales Outstanding. This places Cardio Diagnostics Holdings in the lower half of its industry. The industry median Days Sales Outstanding is 69.00. Cardio Diagnostics Holdings' value of 73.00 is 5.8% above this benchmark. Historically, Cardio Diagnostics Holdings' own Days Sales Outstanding has ranged from 107.35 to 365.00 over the past decade. While the company's 10-year median is 328.50 vs. the industry median of 69.00, Cardio Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.00, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardio Diagnostics Holdings's current Days Sales Outstanding of 73.00 is 5.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cardio Diagnostics Holdings and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardio Diagnostics Holdings's current Days Sales Outstanding is 73.00, which is 78% below median its own 10-year median of 328.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardio Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings (CDIO) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.80, compared to a current price of $2.02 — trading 12.4% above its estimated fair value. The current Days Sales Outstanding is 73.00, which is 78% below median its 10-year median of 328.50 and 5.8% above the Biotechnology industry median of 69.00. Cardio Diagnostics Holdings' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Cardio Diagnostics Holdings (CDIO), the current Days Sales Outstanding is 73.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be overvalued.
The current stock price of $2.02 is trading 12.4% above its estimated GF Value™ of $1.80.
GuruFocus considers Cardio Diagnostics Holdings to be Modestly Overvalued.
Key valuation signals for CDIO:
Days Sales Outstanding: 73.00 (78% below median its 10-year median of 328.50)
GF Value™: $1.80 vs. price of $2.02 (12.4% above fair value)
Industry Position: 5.8% above the Biotechnology median (#723 of 838)
No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
53GF Score
Get the complete analysis for CDIO
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIO has been successfully added to your 
